
TP-3654
CAS No. 1361951-15-6
TP-3654( TP3654 | TP 3654 )
Catalog No. M11491 CAS No. 1361951-15-6
A potent, selective, orally active second-generation PIM inhibitor with Ki of 5, 42 and 239 nM for Pim1, 2 and 3, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 47 | In Stock |
![]() ![]() |
10MG | 69 | In Stock |
![]() ![]() |
25MG | 138 | In Stock |
![]() ![]() |
50MG | 222 | In Stock |
![]() ![]() |
100MG | 334 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameTP-3654
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally active second-generation PIM inhibitor with Ki of 5, 42 and 239 nM for Pim1, 2 and 3, respectively.
-
DescriptionA potent, selective, orally active second-generation PIM inhibitor with Ki of 5, 42 and 239 nM for Pim1, 2 and 3, respectively; exhibits submicromolar activity in UM-UC-3 bladder cancer cell line; displays favorabl hERG and CYP450 inhibition profiles compared with SGI-1776, reduces tumor growth in vivo xenografts.(In Vitro):TP-3654 demonstrates potent PIM-1 specific cellular activity in the PIM-1/BAD overexpression system with an average EC50 of 67 nM. TP-3654 treatment reduces levels of phospho-BAD in vitro using the bladder cancer cell line UM-UC-3. TP-3654 reduces colony growth of T24 and UM-UC3 cells, confirming the PIM-1–dependent growth for both cell lines.(In Vivo):Oral dosing of 200 mg/kg TP-3654 significantly reduces both UM-UC-3 and PC-3 tumor growth measured by volume (caliper) and by final tumor weight, with no significant changes in body weight or gross adverse toxicity.
-
In VitroTP-3654 demonstrates potent PIM-1 specific cellular activity in the PIM-1/BAD overexpression system with an average EC50 of 67 nM. TP-3654 treatment reduces levels of phospho-BAD in vitro using the bladder cancer cell line UM-UC-3. TP-3654 reduces colony growth of T24 and UM-UC3 cells, confirming the PIM-1–dependent growth for both cell lines.
-
In VivoOral dosing of 200 mg/kg TP-3654 significantly reduces both UM-UC-3 and PC-3 tumor growth measured by volume (caliper) and by final tumor weight, with no significant changes in body weight or gross adverse toxicity.
-
SynonymsTP3654 | TP 3654
-
PathwayJAK/STAT Signaling
-
TargetPim
-
RecptorPim-1|Pim-2|Pim-3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1361951-15-6
-
Formula Weight418.4553096
-
Molecular FormulaC22H25F3N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESOC(C)(C)[C@H]1CC[C@H](NC2=NN3C(C=C2)=NC=C3C4=CC=CC(C(F)(F)F)=C4)CC1
-
Chemical NameCyclohexanemethanol, α,α-dimethyl-4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]-, trans-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Foulks JM, et al. Neoplasia. 2014 May;16(5):403-12.
molnova catalog



related products
-
INCB053914
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.
-
NMS-P645
NMS-P645 is a novel selective inhibitor of pan-Pim kinases with IC50 of 3/73/12 nM for Pim1/2/3, respectively.
-
SGI-1776
SGI-1776 is a potent, selective, orally active Pim kinase inhibitor with IC50 of 7, 363 and 69 nM for Pim1, Pim2 and Pim3, respectively.